A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease Post author: Post published:May 6, 2026 Post category: Continue ReadingA Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1 Post author: Post published:May 6, 2026 Post category: Continue ReadingSafety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases Post author: Post published:May 6, 2026 Post category: Continue ReadingA Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED Post author: Post published:May 6, 2026 Post category: Continue ReadingTrial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis Post author: Post published:May 6, 2026 Post category: Continue ReadingRESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
AB-1002 in Patients With Class III Heart Failure Post author: Post published:May 6, 2026 Post category: Continue ReadingAB-1002 in Patients With Class III Heart Failure
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis Post author: Post published:May 6, 2026 Post category: Continue ReadingKYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
RAPA-501 Therapy of ALS Expanded Access Protocol Post author: Post published:May 6, 2026 Post category: Continue ReadingRAPA-501 Therapy of ALS Expanded Access Protocol
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP) Post author: Post published:May 6, 2026 Post category: Continue ReadingSafety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis Post author: Post published:May 6, 2026 Post category: Continue ReadingStudy to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
